Low toxicity and favorable clinical and quality of life impact after non-myeloablative autologous hematopoietic stem cell transplant in Crohn’s disease
| Autor: | Lilian Piron-Ruiz, Rubens Camargo Siqueira, Roberto Luiz Kaiser, Luiz Gustavo de Quadros, Fernanda Soubhia Liedtke Kaiser, Tatiana Peña-Arciniegas, Mikaell Alexandre Gouvea Faria, Flavio Fontes Pirozzi, Milton Artur Ruiz, Richard K. Burt |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male medicine.medical_specialty Cyclophosphamide Anemia medicine.medical_treatment lcsh:Medicine Hematopoietic stem cell transplantation Neutropenia Gastroenterology Transplantation Autologous General Biochemistry Genetics and Molecular Biology 03 medical and health sciences Young Adult 0302 clinical medicine Crohn Disease Internal medicine medicine Humans lcsh:Science (General) lcsh:QH301-705.5 Leukopenia business.industry lcsh:R Hematopoietic Stem Cell Transplantation Hematopoietic stem cell General Medicine Middle Aged medicine.disease Surgery Transplantation Research Note medicine.anatomical_structure lcsh:Biology (General) 030220 oncology & carcinogenesis Quality of Life 030211 gastroenterology & hepatology Female Lymphocytopenia medicine.symptom business medicine.drug lcsh:Q1-390 |
| Zdroj: | BMC Research Notes, Vol 10, Iss 1, Pp 1-7 (2017) BMC Research Notes |
| ISSN: | 1756-0500 |
| DOI: | 10.1186/s13104-017-2824-1 |
| Popis: | Objective The incidence of adverse events in myeloablative transplant protocols is high in refractory Crohn’s disease; this study used low doses of cyclophosphamide. Fourteen patients were submitted to non-myeloablative autologous hematopoietic stem cell transplantation. Results The average number of days of anemia (hemoglobin 9/L) in the mobilization phase was 1.7 ± 1.5 while it was 7.6 ± 1.4 in the conditioning phase. When comparing the conditioning and mobilization phases, there was an increased number days of leukopenia (white blood cells 9/L), lymphocytopenia (lymphocytes 9/L) and thrombocytopenia (platelets 9/L). Crohn’s Disease Activity Index values before the transplant ranged from 155 to 450.5 (mean 281.2 ± 79.0) and at 30 days after the procedures they ranged from 45.4 to 177 (mean 95.8 ± 35.4). Moreover, the procedure improved in overall quality of life of patients. Non-myeloablative autologous hematopoietic stem cell transplantation with lower doses of cyclophosphamide leads to lower rates of hematological toxicity and adverse events compared to protocols described in the literature. Trial registration NCT 03000296: Date 9 December 2016 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|